Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 14, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2023-07-24
DOI
10.3389/fimmu.2023.1199145
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression
- (2023) Alessia Gravina et al. NATURE BIOTECHNOLOGY
- The emerging roles of γδ T cells in cancer immunotherapy
- (2023) Sofia Mensurado et al. Nature Reviews Clinical Oncology
- Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
- (2023) Sham Mailankody et al. NATURE MEDICINE
- IL-33 promotes double negative T cell survival via the NF-κB pathway
- (2023) Xiaojing Sun et al. Cell Death & Disease
- Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes
- (2023) Alex Look et al. Frontiers in Immunology
- Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non–Gene-edited Allogeneic CAR T-Cell Therapy
- (2022) Alexandre Michaux et al. JOURNAL OF IMMUNOTHERAPY
- CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer
- (2022) Zhiheng Wu et al. Frontiers in Immunology
- Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models
- (2022) Kevin P Nishimoto et al. Clinical & Translational Immunology
- 3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells
- (2022) Zhiqiang Wang et al. Cell Stem Cell
- Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
- (2022) Alexander Dimitri et al. Molecular Cancer
- FDA approves second BCMA-targeted CAR-T cell therapy
- (2022) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT
- (2022) Hana Andrlová et al. Science Translational Medicine
- Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
- (2022) Mayumi Sugita et al. Nature Communications
- Next-Generation CAR T-cell Therapies
- (2022) Regina M. Young et al. Cancer Discovery
- Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities
- (2022) Daniel Vasic et al. Science Immunology
- EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity
- (2022) Ran Jing et al. Cell Stem Cell
- Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage
- (2022) Alessio David Nahmad et al. NATURE BIOTECHNOLOGY
- Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing
- (2022) Sumin Jo et al. Nature Communications
- Engineering Human MAIT Cells with Chimeric Antigen Receptors for Cancer Immunotherapy
- (2022) Mikail Dogan et al. JOURNAL OF IMMUNOLOGY
- The journey of CAR-T therapy in hematological malignancies
- (2022) Junru Lu et al. Molecular Cancer
- Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia
- (2022) Giorgio Ottaviano et al. Science Translational Medicine
- Target tumor microenvironment by innate T cells
- (2022) Yan-Ruide Li et al. Frontiers in Immunology
- UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
- (2022) Reuben Benjamin et al. Lancet Haematology
- Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia
- (2022) Diego Sánchez Martínez et al. Journal for ImmunoTherapy of Cancer
- Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
- (2022) Amitkumar Mehta et al. BLOOD
- Mucosal-associated invariant T cells for cancer immunotherapy
- (2022) Yan-Ruide Li et al. MOLECULAR THERAPY
- The SIRPα–CD47 immune checkpoint in NK cells
- (2021) Tobias Deuse et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy
- (2021) Shoichi Iriguchi et al. Nature Communications
- CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia
- (2021) Yongxian Hu et al. CLINICAL CANCER RESEARCH
- Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells ‘off the shelf’?
- (2021) Amanda M. DiNofia et al. Nature Reviews Clinical Oncology
- Expansion of donor-unrestricted MAIT cells with enhanced cytolytic function suitable for TCR redirection
- (2021) Tiphaine Parrot et al. JCI Insight
- Chromothripsis as an on-target consequence of CRISPR–Cas9 genome editing
- (2021) Mitchell L. Leibowitz et al. NATURE GENETICS
- Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells
- (2021) Bo Wang et al. Nature Biomedical Engineering
- Mutant B2M‐HLA‐E and B2M‐HLA‐G fusion proteins protects universal chimeric antigen receptor‐modified T cells from allogeneic NK cell‐mediated lysis
- (2021) Yelei Guo et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- DL4-μbeads induce T cell lineage differentiation from stem cells in a stromal cell-free system
- (2021) Ashton C. Trotman-Grant et al. Nature Communications
- Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform
- (2021) Ahmad-Samer Al-Homsi et al. BLOOD
- Allogeneic NKT Cells Expressing a CD19-Specific CAR in Patients with Relapsed or Refractory B-Cell Malignancies: An Interim Analysis
- (2021) Carlos A. Ramos et al. BLOOD
- A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing
- (2021) Sanju Sinha et al. Nature Communications
- Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma
- (2021) Amani Makkouk et al. Journal for ImmunoTherapy of Cancer
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
- (2020) S. Depil et al. NATURE REVIEWS DRUG DISCOVERY
- CRISPR-engineered T cells in patients with refractory cancer
- (2020) Edward A. Stadtmauer et al. SCIENCE
- CYAD-101: An innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy.
- (2020) Hans Prenen et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy
- (2020) Yuki Kagoya et al. Cancer Immunology Research
- Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR
- (2020) Dana Stenger et al. BLOOD
- Cancer immunotherapy with γδ T cells: many paths ahead of us
- (2020) Dieter Kabelitz et al. Cellular & Molecular Immunology
- Engineered off-the-shelf therapeutic T cells resist host immune rejection
- (2020) Feiyan Mo et al. NATURE BIOTECHNOLOGY
- Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
- (2020) Meir Rozenbaum et al. Frontiers in Immunology
- MAIT Cell Development and Functions: the Microbial Connection
- (2020) François Legoux et al. IMMUNITY
- Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
- (2020) Andras Heczey et al. NATURE MEDICINE
- Eradication of T-ALL cells by CD7 targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management
- (2020) Shiqi Li et al. CLINICAL CANCER RESEARCH
- Organoid-Induced Differentiation of Conventional T Cells from Human Pluripotent Stem Cells
- (2019) Amélie Montel-Hagen et al. Cell Stem Cell
- Developing allogeneic double negative T cells as a novel off-the-shelf adoptive cellular therapy for cancer
- (2019) Jong Bok Lee et al. CLINICAL CANCER RESEARCH
- Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15
- (2019) Junlin Yao et al. Journal for ImmunoTherapy of Cancer
- Mechanisms of resistance to CAR T cell therapy
- (2019) Nirali N. Shah et al. Nature Reviews Clinical Oncology
- Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients
- (2019) Tobias Deuse et al. NATURE BIOTECHNOLOGY
- Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade
- (2019) Linan Fang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Manufacturing chimeric antigen receptor T cells: issues and challenges
- (2019) Claire Roddie et al. CYTOTHERAPY
- Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility
- (2019) Huaigeng Xu et al. Cell Stem Cell
- α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials
- (2019) Yingting Zhang et al. Frontiers in Immunology
- Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote ex vivo Lysis of Leukemic Blasts in a CD1d-Dependent Manner
- (2019) Simona Jahnke et al. Frontiers in Immunology
- NKT cells co-expressing a GD2-specific chimeric antigen receptor and IL-15 show enhanced in vivo persistence and antitumor activity against neuroblastoma
- (2019) Xin Xu et al. CLINICAL CANCER RESEARCH
- Cell Biology of T Cell Receptor Expression and Regulation
- (2018) Andrés Alcover et al. Annual Review of Immunology
- The potential role of γδ T cells after allogeneic HCT for leukemia
- (2018) Rupert Handgretinger et al. BLOOD
- Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation
- (2018) Anna Capsomidis et al. MOLECULAR THERAPY
- Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements
- (2018) Michael Kosicki et al. NATURE BIOTECHNOLOGY
- p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells
- (2018) Robert J. Ihry et al. NATURE MEDICINE
- CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
- (2018) Emma Haapaniemi et al. NATURE MEDICINE
- IL-21 Selectively Protects CD62L+NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy
- (2018) Ho Ngai et al. JOURNAL OF IMMUNOLOGY
- Standardizing CAR-T therapy: Getting it scaled up
- (2018) Xiaofeng Dai et al. BIOTECHNOLOGY ADVANCES
- Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting
- (2018) Antonia Rotolo et al. CANCER CELL
- Allogeneic CAR-T Cells: More than Ease of Access?
- (2018) Charlotte Graham et al. Cells
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
- (2017) Germán G Gornalusse et al. NATURE BIOTECHNOLOGY
- Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
- (2017) Waseem Qasim et al. Science Translational Medicine
- Cytokine-free directed differentiation of human pluripotent stem cells efficiently produces hemogenic endothelium with lymphoid potential
- (2017) Yekaterina Galat et al. Stem Cell Research & Therapy
- CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
- (2016) Xiaojuan Liu et al. CELL RESEARCH
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- Mucosal-associated invariant T-cell activation and accumulation after in vivo infection depends on microbial riboflavin synthesis and co-stimulatory signals
- (2016) Z Chen et al. Mucosal Immunology
- Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
- (2015) Laurent Poirot et al. CANCER RESEARCH
- New Cell Sources for T Cell Engineering and Adoptive Immunotherapy
- (2015) Maria Themeli et al. Cell Stem Cell
- Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy
- (2014) A. Heczey et al. BLOOD
- Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer
- (2014) Eva-Maria Surmann et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Direct induction of haematoendothelial programs in human pluripotent stem cells by transcriptional regulators
- (2014) Irina Elcheva et al. Nature Communications
- A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
- (2012) H. Torikai et al. BLOOD
- T Lymphocyte Potential Marks the Emergence of Definitive Hematopoietic Progenitors in Human Pluripotent Stem Cell Differentiation Cultures
- (2012) Marion Kennedy et al. Cell Reports
- Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy
- (2011) S Merims et al. LEUKEMIA
- Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells
- (2010) M. Dusseaux et al. BLOOD
- The HLA genomic loci map: expression, interaction, diversity and disease
- (2009) Takashi Shiina et al. JOURNAL OF HUMAN GENETICS
- Generation of T Cells from Human Embryonic Stem Cell-Derived Hematopoietic Zones
- (2009) F. Timmermans et al. JOURNAL OF IMMUNOLOGY
- Interaction of KLRG1 with E-cadherin: New functional and structural insights
- (2008) Stephan Rosshart et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More